- Home
- VIGL vs SGA Comparison
VIGL vs SGA Comparison
Compare VIGL & SGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- SGA
- Stock Information
- Founded
- VIGL 2020
- SGA 1986
- Country
- VIGL United States
- SGA United States
- Employees
- VIGL N/A
- SGA N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- SGA Broadcasting
- Sector
- VIGL Health Care
- SGA Consumer Discretionary
- Exchange
- VIGL Nasdaq
- SGA Nasdaq
- Market Cap
- VIGL 89.3M
- SGA 79.0M
- IPO Year
- VIGL 2022
- SGA 1992
- Fundamental
- Price
- VIGL $1.68
- SGA $12.40
- Analyst Decision
- VIGL Strong Buy
- SGA
- Analyst Count
- VIGL 5
- SGA 0
- Target Price
- VIGL $16.33
- SGA N/A
- AVG Volume (30 Days)
- VIGL 159.5K
- SGA 15.3K
- Earning Date
- VIGL 03-13-2025
- SGA 03-11-2025
- Dividend Yield
- VIGL N/A
- SGA 8.20%
- EPS Growth
- VIGL N/A
- SGA N/A
- EPS
- VIGL N/A
- SGA 0.55
- Revenue
- VIGL N/A
- SGA $110,294,000.00
- Revenue This Year
- VIGL N/A
- SGA $2.92
- Revenue Next Year
- VIGL N/A
- SGA N/A
- P/E Ratio
- VIGL N/A
- SGA $22.55
- Revenue Growth
- VIGL N/A
- SGA N/A
- 52 Week Low
- VIGL $1.49
- SGA $10.75
- 52 Week High
- VIGL $6.06
- SGA $23.56
- Technical
- Relative Strength Index (RSI)
- VIGL 32.05
- SGA 53.29
- Support Level
- VIGL $1.74
- SGA $12.15
- Resistance Level
- VIGL $1.94
- SGA $12.80
- Average True Range (ATR)
- VIGL 0.16
- SGA 0.42
- MACD
- VIGL -0.02
- SGA 0.03
- Stochastic Oscillator
- VIGL 4.51
- SGA 52.14
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets and It derives a majority of its revenue from the sale of advertising for broadcast on its stations.